SEC Form 4 · accession 0001209191-17-041954

· CELG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 26, 2017

Accepted (ET)

Jun 27, 2017 · 4:39 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000816284

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jun 26, 2017	M	9,250	$24.97	A	32,877	D
Common Stock^F1	Jun 26, 2017	S	9,250	$133.57	D	23,627	D
Common Stock	Jun 26, 2017	M	9,250	$33.88	A	32,877	D
Common Stock^F1	Jun 26, 2017	S	9,250	$133.57	D	23,627	D
Common Stock^F2	holding	—	—		—	1,800	I	Family Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Common Stock^F4,F3	$24.97	Jun 26, 2017	M	9,250	D	—	Dec 17, 2017	Common Stock	9,250	0	D
Common Stock^F4,F3	$33.88	Jun 26, 2017	M	9,250	D	—	Sep 17, 2017	Common Stock	9,250	0	D

F1The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from $132.86 to $134.35, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3The option was fully exercisable.
F4The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.